Typically, the starting dose in a Phase 1 trial is too low to show efficacy. For CDR Life, observing immunological activity and biomarker improvement in their very first patient was a rare and remarkable event that provided the first tangible sign their scientific platform could become a real therapeutic.

Yale spin-out Bexorg uses donated, post-mortem human brains kept molecularly active to test CNS drugs. This novel platform's key advantage is its ability to directly measure pharmacokinetics and blood-brain barrier penetration in a complex human organ, addressing a primary reason for clinical trial failure that animal and cell models cannot adequately predict.

To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

For its leptomeningeal cancer drug, Plus Therapeutics found the FDA receptive to clinical trial endpoints beyond overall survival. The agency was open to "compartmental based endpoints" measuring efficacy within the targeted CNS area—a significant regulatory shift for non-systemic treatments with no established approval pathway.

An analysis of over 17,000 oncology drug development trajectories revealed that trials incorporating biomarkers had almost twice the overall success probability (10%) compared to those without (5%). This success boost is most significant in early-phase (Phase 1 and 2) trials.

Unlike typical safety-focused Phase 1 trials, Jade's trial for IgA nephropathy in healthy volunteers provides highly translatable efficacy data. Measuring the drop in IgA, a key biomarker, in healthy subjects directly predicts the drug's clinical activity in patients, significantly de-risking later-stage development before treating a single patient.

Neurofilament light chain (NFL) is an undisputed biomarker for neurodegeneration. Consistently negative readings indicate cells are dying less, providing a pure, objective signal that a therapy is working. This data alone should be enough to meet the 'probable benefit' standard for an Accelerated Approval (AA).

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

While designed for the 10% of Parkinson's patients with a specific genetic variant, Gain Therapeutics' trial data shows its drug may benefit a larger group. About 50% of patients without the gene defect also have the toxic lipid buildup the drug targets, suggesting a significantly expanded potential market beyond the initial niche population.